Effects of a combination of niacin and chromium(III)-chloride on the skin and lungs of hyperlipemic rats

Biological Trace Element Research

Volumn 103, Issue 3, 2005, Pages 249-260

  Yanardag, Refiye ^a   Peksel, Aysegul ^b   Yesilyaprak, Bihter ^a   Doger, M Mutluhan ^a   Arisan Atac, Inci ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b YILDIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Chromium; Glutathione; Hyperlipemia; Lipid peroxidation; Lungs; Niacin; Sialic Acid; Skin; Uric acid

Indexed keywords

CHOLESTEROL; CHOLIC ACID; CHROMIUM CHLORIDE; GLUTATHIONE; LIPID; NICOTINIC ACID; SIALIC ACID; SUNFLOWER OIL; URIC ACID;

ALBINISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; GLUTATHIONE METABOLISM; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID DIET; LIPID PEROXIDATION; LUNG; NONHUMAN; RAT; SKIN; TISSUE DISTRIBUTION;

ANIMALS; CHLORIDES; CHROMIUM COMPOUNDS; DIET; FEMALE; GLUTATHIONE; HYPERLIPIDEMIAS; LIPID PEROXIDATION; LUNG; N-ACETYLNEURAMINIC ACID; NIACIN; RANDOM ALLOCATION; RATS; SKIN; URIC ACID;

EID: 18244369737     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1385/BTER:103:3:249     Document Type: Article

References (55)

1. A. Onat, Risk factors and cardiovascular disease in Turkey, Atherosclerosis 156, 1-10 (2001).
2. D. Kromhout, Diet and cardiovascular diseases, J. Nutr. Health Aging 5, 144-149 (2001).
3. S. K. Wattanapitayakul and J. A. Bauer, Oxidative pathways in cardiovascular disease roles, mechanisms and therapeutic implications, Pharmacol. Ther. Pharmacol. 89, 187-206 (2001).
4. H. Esterbauer, G. Wag, and H. Puhl, Lipid peroxidation and its role in atherosclerosis, Br. Med. Bull. 49, 566-576 (1993).
5. J. P. De La Cruz, L. Quintero, M. A. Villalobos, and F. S. De La Cuesta, Lipid peroxidation and glutathione system in hyperlipemic rabbits: influence of olive oil administration, Biochim. Biophys. Acta 1485, 36-44 (2000).
6. S. Kajanachumpol, et al., Plasma lipid peroxide and antioxidant levels in diabetic patients, J. Med. Assoc. Thai. 80, 372-377 (1999).
7. B. Halliwel, Drug antioxidant effects, Drugs 42, 569-605 (1991).
8. J. Loeper, J. Goy, L. Rosensztajn, O. Bedu, and P. Moisson, Lipid peroxidation and protective enzymes during myocardial infarction, Clin. Chim. Acta 196, 119-126 (1991).
9. D. M. Colquhoun, Nutraceuticals: vitamins and other nutrients in coronary heart disease, Curr. Opin. Lipidol. 12, 639-646 (2001).
10. S. B. Lall, S. Bhoopendra, K. Gulati, and S. D. Seth, Role of nutrition in toxic injury, Indian J. Exp. Biol. 37, 109-116 (1999).
11. L. Raij, J. Nagy, K. Coffee, and E. G. DeMaster, Hypercholesterolemia promotes endothelial dysfunction in vitamin E- and selenium-deficient rats, Hypertension 22, 56-61 (1993).
12. S. S. Melo, M. R. Arantes, M. S. Meirelles, A. A. Jordao, and H. Vannuchi, Lipid peroxidation in nicotinamide-deficient and nicotinamide- supplemented rats with streptozotocin-induced diabetes, Acta Diabetol. 37, 33-39 (2000).
13. R. A. Anderson, N. A. Bryden, and M. M. Polansky, Lack of toxicity of chromium chloride and chromium picolinate in rats, J. Am. Coll. Nutr. 16, 273-279 (1997).
14. M. Simonoff, Chromium deficiency and cardiovascular risk, Cardiovasc. Res. 18, 591-596 (1984).
15. T. Zima, O. Mestek, V. Tesar, et al., Chromium levels in patients with internal diseases, Biochem. Mol. Biol. Int. 46, 365-374 (1998).
16. H. L. Figge, J. Figge, P. M. Souney, A. H. Mutnick, and F. Sacks, Nicotinic acid: a review of its clinical use in the treatment of lipid disorders, Pharmacotherapy 8, 287-294 (1988).
17. J. R. Dipalma and W. S Thayer, Use of niacin as a drug, Annu. Rev. Nutr. 11, 169-187 1991.
18. A. C. Goldberg, Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study, Am. J. Cardiol. 82, 35-38 (1998).
19. D. M. Capuzzi, J. M. Morgan, A. O. Brusco, and C. M. Intenzo, Niacin dosing: relationship to benefits and adverse effects, Curr. Atherosclerosis Rep. 2, 64-71 (2000).
20. A. Blazovics, J. Feher, E. Feher, A. K. Petri, and G. Petri, Liver protecting and lipid lowering effects of Sempervivum tectorum extract in the rat, Phytother. Res. 7, 98-100 (1993).
21. J. Ledwozyw, J. Michalak, A. Stepien, and A. Kadziolka, The relationship plasma triglycerides, cholesterol, total lipids and lipid peroxidation products during human atherosclerosis, Clin. Chim. Acta 155, 275-284 (1986).
22. K. Yagi, Assay for blood plasma or serum, Methods Enzymol. 105, 328-337 (1984).
23. E. Beutler, Glutathione, in Red Cell Metabolism: A Manual of Biochemical Methods, 2nd ed., Grune and Stratton, New York, pp. 112-114 (1975).
24. H. O. Lowry, J. N. Rosebrough, A. L. Farr, and J. R. Randall, Protein measurement with the folin phenol reagent, J. Biol. Chem. 193, 265-275 (1951).
25. K. Lorentz, T. Weiss, and E. Kraas, Sialic acid in human serum and cerebrospinal fluid, comparison of methods and references value, Clin. Chem. Clin. Biochem. 24, 189-198 (1986).
26. W. T. Caraway, Determination of uric acid in serum by a carbonate method, Am. J. Clin. Pathol. 25, 840-845 (1955).
27. J. L. Hintze, Copyright C, 865, East 400, North Kaysville, Utah, 84037, (801), 546-0445, (1986).
28. M. F. Maggi-Capeyron, J. Cases, E. Badia, et al., A diet high in cholesterol and deficient in vitamin E induces lipid peroxidation but does not enhance antioxidant enzyme expression in rat liver, J. Nutr. Biochem. 13, 296-301 (2002).
29. R. I. Press, J. Geller, and G. W. Evans, The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects, West. J. Med. 152, 41-45 (1990).
30. L. Gate, J. Paul, G. N. Ba, K. D. Tew, and H. Tapiero, Oxidative stress induced in pathologies: the role of antioxidants, Biomed. Pharmacother. 53, 169-180 (1999).
31. Y. Z. Fang, S. Yang, and G. Wu, Free radicals, antioxidants and nutrition, Nutr. 18, 872-879 (2002).
32. R. Kohen, Skin antioxidants: their role in aging and in oxidative stress-new approaches for their evaluation, Biomed. Pharmacother. 53, 181-192 (1999).
33. R. A. Kozar, C. J. Weibel, J. Cipolla, et al., Antioxidant enzymes are induced during recovery from acute lung injury, Crit. Care Med. 28, 2486-2491 (2000).
34. K. Kedziora Kornatowska, S. Szram, T. Kornatowski, et al., The effect of verapamil on the antioxidant defence system in diabetic kidney, Clin. Chim. Acta 322, 105-112 (2002).
35. M. Hoyos, J. M. Guerrero, R. Perez Cano, et al., Serum cholesterol and lipid peroxidation are decreased by melatonin in diet-induced hypercholesterolemic rats, J. Pineal Res. 28, 150-155 (2000).
36. F. J. Kelly, Glutathione in defence of the lung, Food Chem. Toxicol. 37, 963-966 (1999).
37. I. Seghrouchni, J. Drai, E. Bannier, et al., Oxidative stress parameters in type I, type II and insulin-treated type 2 diabetes mellitus; insulin treatment efficiency, Clin. Chim. Acta 321, 89-96 (2002).
38. S. H. Ganji, V. S. Kamanna, and M. L. Kashyap, Niacin and cholesterol: role in cardiovascular disease, [review], J. Nutr. Biochem. 14, 298-305 (2003).
39. M. H. Davidson, Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events, Curr. Atherosclerosis Rep. 5, 418-422 (2003).
40. D. R. Illingworth, E. A. Stein, Y. B. Mitchel, et al., Comparative effects of lovastatin and niacin in primary hypercholesterolemia a prospective trial. Arch. Intern. Med. 154, 1586-1595 (1994).
41. P. Evans and B. Halliwell, Micronutrients: oxidant/antioxidant status, Br. J. Nutr. 85, 67-74 (2001).
42. Y. Fang, S. Yang, and G. Wu, Free radicals, antioxidants, and nutrition, Nutrition 18, 872-879 (2002).
43. S. Davies, J. Howard, and A. Hunnisett, Age-related decreases in chromium levels in 51,665 hair, sweat and serum samples from 40,872 patients- implications for the prevention of cardiovascular disease and type II diabetes mellitus, Metabolism 46, 469-473 (1997).
44. S. Ueno, N. Susa, Y. Furukawa, et al., Effects of chromium in lipid peroxidation in isolated hepatocytes, Jpn. J. Sci. 50, 45-52 (1998).
45. H. G. Preuss, S. T. Jarrell, R. Scheckenbach, S. Lieberman, and R. A. Anderson, Comparative effects of chromium, vanadium and gymnema sylvestre on sugar-induced blood pressure elevations in SHR, J. Am. Coll. Nutr. 17, 116-123 (1998).
46. R. A. Anderson, A. Roussel, N. Zouari, S. Mahjoub, J. Matheau, and A. Kerkeni, Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus, J. Am. Coll. Nutr. 20, 212-218 (2001).
47. M. Onderci, N. Sahin, K. Sahin, and N. Kiliç, Antioxidant properties of chromium and zinc: in vivo effects on digestibility, lipid peroxidation, antioxidant vitamins, and some minerals under a low ambient temperature, Biol. Trace Element Res. 92, 139-150 (2003).
48. H. H. Cheng, M. H. Lai, W. C. Hou, and C. L. Huang, Antioxidant effects of chromium supplementation with type 2 diabetes mellitus and euglycemic subjects, J. Agric. Food Chem. 52, 1385-1389 (2004).
49. M. Tezuka, S. Ishii, and S. Okada, Chromium(III) decreases carbon tetrachloride originated trichloromethyl radical in mice, Biochemistry 44, 261-265 (1991).
50. Y. Ohara, T. E. Peterson, and D. G. Harison, Hypercholesterolemia increases endothelial superoxide anion production, J. Clin. Invest. 91, 2546-2551 (1993).
51. E. Tremoli, P. Maderna, M. Sirtori, and C. Sirtori, Platelet aggregation and malondialdehyde formation in type IIA hypercholesterolemic patients, Haemostasis 8, 47-53 (1979).
52. M. Saladini, L. Menaube, and E. Ferrari, Binding ability of sialic acid towards biological and toxic metal ions. NMR, potentiometric and spectroscopic study, J. Inorg. Biochem. 88, 61-68 (2002).
53. P. Sillanaukee, M. Pönniö, and K. Seppa, Sialic acid: new potential marker of alcohol abuse, Alcohol. Clin. Exp. Res. 23, 1039-1043 (1999).
54. P. J. Waters, E. Lewry, and C. A. Pennock, Measurement of sialic acid in serum and urine: clinical applications and limitations, Ann. Clin. Biochem. 29, 625-637 (1992).
55. S. Ekin, I. Meral, H. Gunduz, and N. Mert, Comparative study of total protein and total and lipid-associated serum sialic acid levels in patients with type 2 diabetes mellitus, J. Clin. Lab. Anal. 17, 124-126 (2003).